Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

INTRODUCTION: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the treatment of type 2 diabetes (T2D) and more recently for heart failure with or without diabetes. They have been shown to be safe (from the cardiovascular (CV) perspective) and effective (in terms of glycaemia, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Caparrotta, Thomas M., Greenhalgh, Andrew M., Osinski, Karen, Gifford, Robert M., Moser, Svenja, Wild, Sarah H., Reynolds, Rebecca M., Webb, David J., Colhoun, Helen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994468/
https://www.ncbi.nlm.nih.gov/pubmed/33665777
http://dx.doi.org/10.1007/s13300-021-01004-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994468/
https://www.ncbi.nlm.nih.gov/pubmed/33665777
http://dx.doi.org/10.1007/s13300-021-01004-2

Ejemplares similares